Chin Yang Chang

Dr. Chin Yang Chang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in FEBS Open Bio
Verified
Journal Article
Open access
CCChin Yang Chang
Chin Yang Chang
JTJiayu A. Tai
Jiayu A. Tai
YSYuko Sakaguchi
Yuko Sakaguchi
TNTomoyuki Nishikawa
Tomoyuki Nishikawa
YHYayoi Hirayama
Yayoi Hirayama
KYKunihiko Yamashita
Kunihiko Yamashita
Cell-cell fusion involves the fusion of somatic cells into a single hybrid cell. It is not only a physiological process but also an important cell engineering technology which can be applied to various fields, such as regenerative medicine, antibody engineering, genetic engineering, and cancer therapy. There are three major methods of cell fusion: electrical cell fusion, polyethylene glycol (PEG) cell fusion, and virus-mediated cell fusion. Although PEG cell fusion is the most economical approach and does not require expensive instrumentation, it has a poor fusion rate and induces a high rate of cell cytotoxicity. To improve the fusion rate of the PEG method, we combined it with the pyro-drive jet injector (PJI). PJI provides instant pressure instead of cell agitation to increase the probability of cell-to-cell contact and shorten the distance between cells in the process of cell fusion. Here, we report that this improved fusion method not only decreased cell cytotoxicity during the fusion process, but also increased fusion rate compared with the conventional PEG method. Furthermore, we tested the functionality of cells fused using the PJI-PEG method and found them to be comparable to those fused using the conventional PEG method in terms of their application for dendritic cell (DC)-tumor cell fusion vaccine production; in addition, the PJI-PEG method demonstrated excellent performance in hybridoma cell preparation. Taken together, our data indicate that this method improves cell fusion efficiency as compared to the PEG method and thus has the potential for use in various applications that require cell fusion technology.

6 August 2019 in Cancer Gene Therapy
Verified
Journal Article
Open access
JTJiayu A. Tai
Jiayu A. Tai
CCChin Yang Chang
Chin Yang Chang
TNTomoyuki Nishikawa
Tomoyuki Nishikawa
YKYasufumi Kaneda
Yasufumi Kaneda
Inactivated Sendai virus particle (or hemagglutinating virus of Japan envelope; HVJ-E) has been previously reported to possess antitumour properties that activate antitumour immunity. Two glycoproteins, fusion (F) and hemagglutinin-neuraminidase (HN), are present on the surface of HVJ-E. HN is necessary for binding to receptors such as acidic gangliosides, and F induces membrane fusion by associating with membrane lipids. We previously reported that liposomes reconstituted with F but not HN showed antitumour activity by inducing IL-6 secretion in dendritic cells (DCs), suggesting that F protein is capable of eliciting antitumour activity. Here, we attempted to deliver F gene into tumour tissue in mice by electroporation and demonstrated that F gene therapy retarded tumour growth, increased CD4+ and CD8+ T-cell infiltration into tumours and induced tumour-specific IFN-γ T-cell response. However, neutralisation of IL-6R signalling did not impact F plasmid-mediated antitumour effect. Instead, we found that F plasmid treatment resulted in a significant increase in the secretion of the chemokine RANTES (regulated upon activation, normal T cell expressed and secreted) by tumour-infiltrating T cells. Neutralising antibody against RANTES abolished the antitumour effect of F plasmid treatment in a dose-dependent manner. Thus, F gene therapy may show promise as a novel therapeutic for single or combined cancer immunotherapy.

17 June 2026 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
NJNAN JU
NAN JU
CCChin Yang Chang
Chin Yang Chang
HHHiroki Hayashi
Hiroki Hayashi
STShuko Takeda
Shuko Takeda
TKTomohiro Kawano
Tomohiro Kawano
MSMunehisa Shimamura
Munehisa Shimamura
Low circulating levels of soluble fibroblast activation protein (sFAP) are associated with poor outcomes in patients with ischemic stroke, while its function in the ischemic brain remains unclear. This study investigated the role of FAP in ischemic stroke. BALB/c mice were subjected to transient middle cerebral artery occlusion and treated with recombinant FAP (rFAP) or CPD60, a selective FAP inhibitor. Temporal and spatial patterns of FAP expression in brain were analyzed. sFAP showed a greater decrease in CSF than in serum after ischemic stroke. Astrocytes expressed FAP but did not secrete it. Meningeal fibroblasts constitutively released FAP, and this release decreased after exposure to Toll-like receptor (TLR) 4 ligands. In cultured microglial and macrophages, rFAP suppressed TLR2/4-induced cytokine production. rFAP protected neurons and decreased tumor necrosis factor-α and interleukin-1β levels in neuron–glia cultures. Systemic or intracerebroventricular administration of rFAP reduced post-ischemic inflammation and infarct volume, whereas CPD60 worsened tissue injury. FAP also inhibited monocyte migration and inflammation induced by C-C motif chemokine ligand 2 and complement C1q tumor necrosis factor-related protein 6, suggesting that these chemokines are potential substrates. Overall, FAP regulates post-ischemic inflammation and protects neurons after ischemic stroke, indicating its therapeutic potential in ischemic stroke.

27 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
CCChin Yang Chang
Chin Yang Chang
YKYu-Diao Kuan
Yu-Diao Kuan
JTJiayu A. Tai
Jiayu A. Tai
NJNAN JU
NAN JU
YLYen-Liang Li
Yen-Liang Li
MSMunehisa Shimamura
Munehisa Shimamura
Background/Objectives: Whole-cell vaccines have demonstrated clinical potential in cancer treatment and recurrence prevention, yet their immunogenicity and dendritic cell (DC) activation remain suboptimal. This study aimed to evaluate whether a needle-free injector (NFI) could enhance the immunogenicity and antitumor efficacy of whole-cell tumor vaccines. Methods: Adaptive immune responses induced by NFI and traditional syringe injection (SYI) were compared following whole-cell vaccine administration. The morphology of vaccine fluid ejected by NFI and SYI was examined, and the effects on DC antigen uptake and activation were assessed. Antitumor efficacy was further evaluated in MC38 colon adenocarcinoma challenge models. Results: NFI administration elicited stronger antigen-specific adaptive immune responses than SYI. The high-velocity pressure generated by NFI resulted in fragmentation of whole-cell vaccine material, and this morphological alteration was associated with enhanced DC antigen uptake and activation. These immunological improvements corresponded with superior tumor suppression in MC38 models following NFI-delivered vaccination. Conclusions: NFI delivery enhances the immunogenicity and antitumor efficacy of whole-cell tumor vaccines. These findings suggest that needle-free injectors may serve as a simple and effective strategy to improve the performance of whole-cell cancer vaccines.